Ardsley Advisory Partners LP Invests $5.95 Million in ADMA Biologics Inc $ADMA

Key Points

• Ardsley Advisory Partners LP purchased 300,000 shares of ADMA Biologics, valued at approximately $5.95 million, indicating strong institutional interest in the biotechnology firm.
• ADMA Biologics reported $0.15 earnings per share for the latest quarter, exceeding expectations and reflecting a 13.8% year-over-year increase in revenue.
• Analysts have mixed ratings on ADMA Biologics, with one firm downgrading it to "sell" while another raised its price target from $25 to $32 with a "strong-buy" rating.

Ardsley Advisory Partners LP acquired a new position in shares of ADMA Biologics Inc (NASDAQ:ADMA - Free Report) in the 1st quarter, according to its most recent disclosure with the SEC. The fund acquired 300,000 shares of the biotechnology company's stock, valued at approximately $5,952,000. Ardsley Advisory Partners LP owned about 0.13% of ADMA Biologics at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Skandinaviska Enskilda Banken AB publ purchased a new stake in shares of ADMA Biologics in the first quarter valued at about $35,000. SVB Wealth LLC purchased a new stake in shares of ADMA Biologics in the first quarter valued at about $35,000. Smartleaf Asset Management LLC lifted its holdings in shares of ADMA Biologics by 161.4% in the first quarter. Smartleaf Asset Management LLC now owns 2,418 shares of the biotechnology company's stock valued at $49,000 after purchasing an additional 1,493 shares in the last quarter. Tsfg LLC acquired a new position in shares of ADMA Biologics in the first quarter valued at approximately $51,000. Finally, Brooklyn Investment Group raised its position in shares of ADMA Biologics by 28,655.6% in the first quarter. Brooklyn Investment Group now owns 2,588 shares of the biotechnology company's stock valued at $51,000 after buying an additional 2,579 shares during the last quarter. 75.68% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, Director Steve Elms sold 194,749 shares of the company's stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $20.24, for a total transaction of $3,941,719.76. Following the completion of the transaction, the director owned 87,330 shares of the company's stock, valued at approximately $1,767,559.20. This represents a 69.04% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders have sold a total of 425,621 shares of company stock worth $8,829,333 over the last ninety days. Corporate insiders own 3.70% of the company's stock.

ADMA Biologics Trading Down 1.3%

ADMA stock traded down $0.23 on Monday, hitting $16.65. 903,497 shares of the company were exchanged, compared to its average volume of 3,122,465. ADMA Biologics Inc has a twelve month low of $13.50 and a twelve month high of $25.67. The company has a debt-to-equity ratio of 0.21, a current ratio of 5.33 and a quick ratio of 2.78. The business's fifty day moving average is $17.67 and its two-hundred day moving average is $18.97. The stock has a market capitalization of $3.97 billion, a price-to-earnings ratio of 19.35 and a beta of 0.54.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The biotechnology company reported $0.15 EPS for the quarter, topping the consensus estimate of $0.14 by $0.01. ADMA Biologics had a net margin of 44.06% and a return on equity of 41.01%. The firm had revenue of $121.98 million during the quarter, compared to analyst estimates of $121.77 million. During the same quarter in the prior year, the business posted $0.13 earnings per share. ADMA Biologics's revenue for the quarter was up 13.8% compared to the same quarter last year. As a group, research analysts forecast that ADMA Biologics Inc will post 0.51 earnings per share for the current year.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.